Universitätsklinik PIUS Hospital, Innere Medizin
Welcome,         Profile    Billing    Logout  
 9 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Griesinger, Frank
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Recruiting
4
136
Europe
Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed
Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non-Small Cell Lung Cancer Metastatic
10/25
10/26
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
FIND, NCT03827850 / 2018-000399-13: FGFR Inhibitor in FGFR Dysregulated Cancer

Terminated
2
22
Europe
ERDAFITINIB, JNJ -42756493, WHO NUMBER 10147
Lung Cancer Group Cologne
Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer, NSCLC Stage IV
09/22
10/22
PACE-LUNG, NCT05281406 / 2019-004757-88: Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment

Recruiting
2
50
Europe
Osimertinib, Tagrisso, Pemetrexed, Cisplatin, Carboplatin
Goethe University
NSCLC Stage IIIB, NSCLC Stage IV
11/23
11/26
NCT04318938: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Active, not recruiting
2
118
Europe
Brigatinib, Study treatment, Tyrosine kinase inhibitor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Takeda
NSCLC
01/26
01/26
PACCELIO, NCT06102057 / 2022-003408-33: - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Recruiting
2
110
Europe
standard Radiotherapy, standard, Chemotherapy, Immunotherapy, Experimental Radiotherapy, Experimental
TheraOp, AstraZeneca
Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable
06/26
06/28
LCNEC-ALPINE, NCT05470595 / 2020-002683-31: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Active, not recruiting
2
67
Europe
Atezolizumab
Technische Universität Dresden, Roche Pharma AG
Large Cell Neuroendocrine Carcinoma of the Lung
01/28
01/29
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Recruiting
N/A
1050
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
CRISP, NCT02622581: Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Recruiting
N/A
12400
Europe
data collection
AIO-Studien-gGmbH, AstraZeneca, Celgene Corporation, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, iOMEDICO AG, Eli Lilly and Company, Roche Pharma AG, Takeda, Amgen, Janssen-Cilag G.m.b.H, GlaxoSmithKline Research & Development Limited, Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Gilead Sciences
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage II, Non Small Cell Lung Cancer Stage III, Small-cell Lung Cancer, Non-small Cell Lung Cancer Stage I
09/26
12/27
Conradi, Imme
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
NCT03474744 / 2017-003150-16: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Active, not recruiting
2
36
Europe
Copanlisib, Aliqopa, Rituximab, Truxima
Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer
Marginal Zone Lymphoma
06/24
12/29

Download Options